Pricing Log in Create free account

Ultragenyx Pharmaceutical Inc. (RARE) vs Stoke Therapeutics, Inc. (STOK)

Ultragenyx Pharmaceutical Inc. and Stoke Therapeutics, Inc. are both Biotechnology companies. Ultragenyx Pharmaceutical Inc. and Stoke Therapeutics, Inc. are of similar size ($1.7B and $1.7B). Ultragenyx Pharmaceutical Inc. grew revenue faster over the last twelve months: 15.8% against −86.3%. Ultragenyx Pharmaceutical Inc. has the higher net margin (−71.7% vs −862.1%) and the higher return on invested capital (0.00% vs −482.0%). Across the 15 metrics below, Ultragenyx Pharmaceutical Inc. leads on 10 and Stoke Therapeutics, Inc. on 5.

Valuation

Metric RARE STOK Biotechnology median
P/E n/m n/m 11.36
P/S 2.25 64.85 9.12
P/B n/m 5.19 2.14
Price to free cash flow n/m n/m 26.34
EV/EBITDA n/m n/m 0.62
EV/Sales 1.89 53.53 8.56
Earnings yield (32.17%) (14.19%) (34.18%)
Free cash flow yield (27.15%) (11.79%) (23.62%)

Profitability

Metric RARE STOK Biotechnology median
Gross margin 82.88% 100.00% 67.24%
Operating margin (63.98%) (913.12%) 0.00%
Net margin (71.72%) (862.07%) 0.00%
Free cash flow margin (61.20%) (764.66%) 0.00%
Return on equity 285.46% (73.62%) (50.28%)
Return on assets (44.05%) (63.42%) (45.89%)
Return on invested capital 0.00% (482.02%) 0.00%

Growth

Metric RARE STOK Biotechnology median
Revenue growth (TTM) 15.78% (86.28%) 6.96%
EPS growth (last fiscal year) 7.31% 92.73% 29.86%
Revenue growth, 5-year CAGR 19.95% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RARE STOK Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.40 7.24 4.72
Net debt to EBITDA 1.35 14.29 1.01

Dividend

Metric RARE STOK Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric RARE STOK Biotechnology median
Market cap 1.66b 1.71b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack